PubRank

Guido Sauter

Author PubWeight™ 308.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011 12.52
2 Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002 5.99
3 Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002 5.20
4 Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007 5.19
5 Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004 4.94
6 HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009 3.37
7 Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002 3.32
8 Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med 2012 3.29
9 Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013 3.08
10 Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005 2.85
11 Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011 2.78
12 Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol 2009 2.76
13 Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol 2008 2.72
14 Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003 2.71
15 Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004 2.55
16 Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2010 2.48
17 POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003 2.45
18 Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 2004 2.44
19 Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol 2007 2.41
20 Prevalence of KIT expression in human tumors. J Clin Oncol 2004 2.40
21 Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 2008 2.32
22 Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004 2.32
23 Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005 2.31
24 High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004 2.14
25 The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2005 2.10
26 Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011 2.08
27 Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer 2002 2.04
28 Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004 2.04
29 Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004 1.95
30 DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 2006 1.80
31 Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012 1.80
32 Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol 2011 1.77
33 ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011 1.75
34 Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 2004 1.75
35 High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006 1.74
36 Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004 1.68
37 SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006 1.66
38 AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch 2008 1.61
39 Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002 1.59
40 Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2006 1.56
41 Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005 1.55
42 Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 2009 1.52
43 Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008 1.51
44 Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003 1.51
45 Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. Eur Urol 2009 1.51
46 Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2010 1.51
47 Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate 2014 1.50
48 Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007 1.49
49 VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002 1.48
50 The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004 1.44
51 Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003 1.43
52 CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013 1.42
53 E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004 1.40
54 Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007 1.36
55 Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004 1.35
56 Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004 1.33
57 Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2009 1.31
58 Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004 1.31
59 Different types of microsatellite instability in ovarian carcinoma. Int J Cancer 2004 1.30
60 Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 2005 1.30
61 Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol 2003 1.29
62 High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2010 1.28
63 KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004 1.28
64 Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010 1.28
65 Cyclin E overexpression and amplification in human tumours. J Pathol 2003 1.27
66 Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol 2011 1.26
67 The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 2011 1.26
68 TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 2011 1.26
69 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
70 HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2006 1.24
71 High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 2002 1.24
72 Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004 1.23
73 Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol 2013 1.22
74 Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012 1.21
75 Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clin Cancer Res 2005 1.21
76 EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 2005 1.21
77 Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 2012 1.20
78 Tissue microarrays. Biotechniques 2004 1.20
79 Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. Exp Mol Pathol 2012 1.20
80 Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol 2013 1.19
81 Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006 1.17
82 HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 2004 1.15
83 Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010 1.14
84 Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002 1.14
85 Is it time for a new TNM classification in esophageal carcinoma? Ann Surg 2008 1.12
86 Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res 2009 1.12
87 Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 2002 1.11
88 L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007 1.10
89 RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer 2012 1.10
90 Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006 1.09
91 Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006 1.07
92 Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem 2013 1.07
93 Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 2011 1.07
94 Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2010 1.06
95 SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate 2013 1.06
96 Association of osteonecrosis and failure of hip resurfacing arthroplasty. Clin Orthop Relat Res 2009 1.05
97 Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 2007 1.04
98 Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2009 1.03
99 Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002 1.02
100 Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2012 1.02
101 Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol 2010 1.01
102 Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol 2006 1.01
103 Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2012 1.00
104 Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009 1.00
105 Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008 1.00
106 Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 2005 1.00
107 TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 2004 1.00
108 HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003 0.99
109 Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 2005 0.99
110 Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol 2012 0.99
111 Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 2011 0.98
112 Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics 2009 0.98
113 Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 2012 0.98
114 Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res 2012 0.97
115 Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res 2004 0.97
116 Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010 0.96
117 ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 2011 0.96
118 Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. Genes Chromosomes Cancer 2012 0.96
119 Femoral component loosening after hip resurfacing arthroplasty. Skeletal Radiol 2010 0.96
120 Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 2010 0.96
121 A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 2006 0.96
122 Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol 2006 0.95
123 Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. J Urol 2010 0.95
124 Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn 2003 0.95
125 Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009 0.95
126 Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer 2014 0.95
127 Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Mod Pathol 2010 0.95
128 Role of KCNMA1 in breast cancer. PLoS One 2012 0.94
129 11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma. Diagn Mol Pathol 2012 0.94
130 Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol 2015 0.94
131 High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003 0.94
132 MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res 2011 0.93
133 Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PLoS One 2011 0.93
134 Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. J Proteome Res 2010 0.93
135 Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 2010 0.92
136 High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 2012 0.92
137 Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009 0.92
138 Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res 2011 0.91
139 Tissue microarrays. Methods Mol Med 2005 0.90
140 Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Hum Pathol 2009 0.90
141 Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Exp Mol Pathol 2013 0.90
142 High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch 2011 0.90
143 Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch 2014 0.90
144 Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol 2012 0.90
145 The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy. Int J Urol 2010 0.90
146 High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol 2013 0.89
147 Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer 2014 0.89
148 A polylinker approach to reductive loop swaps in modular polyketide synthases. Chembiochem 2008 0.89
149 Tissue microarray (TMA) applications: implications for molecular medicine. Expert Rev Mol Med 2003 0.89
150 The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol 2007 0.89
151 Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget 2014 0.89
152 High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology 2011 0.89
153 Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 2012 0.89
154 Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Res 2012 0.89
155 Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma. J Oral Pathol Med 2013 0.88
156 Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology 2010 0.88
157 Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res 2012 0.88
158 High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005 0.88
159 L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006 0.88
160 Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Mol Cancer 2011 0.88
161 CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Investig 2013 0.88
162 Intraosseous lymphocytic infiltrates after hip resurfacing arthroplasty : a histopathological study on 181 retrieved femoral remnants. Virchows Arch 2009 0.88
163 Estrogen receptor gene amplification occurs rarely in ovarian cancer. Mod Pathol 2008 0.87
164 Abundant expression of AMACR in many distinct tumour types. Pathology 2006 0.86
165 Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 2012 0.86
166 Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J Clin Pathol 2006 0.86
167 High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer 2005 0.86
168 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer 2010 0.86
169 Morphologic analysis of periprosthetic fractures after hip resurfacing arthroplasty. J Bone Joint Surg Am 2010 0.86
170 Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer 2012 0.85
171 Expression and amplification of therapeutic target genes in retinoblastoma. Graefes Arch Clin Exp Ophthalmol 2004 0.85
172 Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res 2005 0.85
173 Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet 2009 0.85
174 Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. Am J Clin Pathol 2007 0.85
175 Molecular staging of prostate cancer in the year 2007. World J Urol 2007 0.85
176 Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J Clin Pathol 2013 0.84
177 High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. Am J Surg Pathol 2005 0.84
178 Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011 0.84
179 L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors. Ann Surg Oncol 2007 0.84
180 Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003 0.84
181 ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 2011 0.84
182 The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. Int J Cancer 2014 0.83
183 Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Hum Pathol 2013 0.83
184 Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002 0.83
185 Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett 2013 0.83
186 Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology 2009 0.83
187 Immunohistochemical profiling of Wilms tumor: a tissue microarray study. Appl Immunohistochem Mol Morphol 2008 0.83
188 Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study. Pathol Oncol Res 2010 0.83
189 High mitochondria content is associated with prostate cancer disease progression. Mol Cancer 2013 0.82
190 Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J Oral Pathol Med 2014 0.82
191 Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010 0.82
192 Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol 2007 0.82
193 The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 2011 0.82
194 Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice. Genes Chromosomes Cancer 2013 0.82
195 High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp Ther Med 2012 0.82
196 Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma. J Oral Pathol Med 2013 0.81
197 PTEN deletion is rare but often homogeneous in gastric cancer. J Clin Pathol 2012 0.81
198 MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Res 2014 0.81
199 Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum Pathol 2008 0.81
200 Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2012 0.81
201 Tissue microarrays for high-throughput molecular pathology. Ann Saudi Med 2004 0.81
202 L1 is highly expressed in tumors of the nervous system: a study of over 8000 human tissues. J Surg Res 2010 0.81
203 Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate 2011 0.80
204 Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. J Appl Genet 2011 0.80
205 Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. Clin Cancer Res 2006 0.80
206 Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002 0.80
207 Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. J Cancer Res Clin Oncol 2013 0.80
208 PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology 2013 0.80
209 The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol 2004 0.80
210 MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. Cancer Biomark 2011 0.80
211 Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. Oncology 2008 0.80
212 Challenges and opportunities for Erlotinib (Tarceva): what does the future hold? Semin Oncol 2003 0.80
213 P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region. Clin Oral Investig 2013 0.80
214 Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer. Am J Surg 2007 0.80
215 Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). J Craniomaxillofac Surg 2013 0.79
216 Tissue microarrays. Methods Mol Biol 2010 0.79
217 High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers. Histopathology 2012 0.79
218 MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. Int J Cancer 2013 0.79
219 Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest 2002 0.79
220 Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol 2009 0.79
221 Introducing tissue microarrays to molecular pathology. Clin Chem 2012 0.79
222 Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. Oral Oncol 2012 0.79
223 Unilateral prostate cancer cannot be accurately predicted in low-risk patients. Int J Radiat Oncol Biol Phys 2009 0.78
224 Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol 2005 0.78
225 Tissue microarrays. Methods Mol Med 2004 0.78
226 Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. Anticancer Res 2013 0.78
227 Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. Ann Surg Oncol 2010 0.78
228 Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer. Clin Cancer Res 2014 0.78
229 Immunoexpression analysis and prognostic value of BLCAP in breast cancer. PLoS One 2012 0.78
230 Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi Med J 2006 0.78
231 MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. Histopathology 2013 0.78
232 Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. PLoS One 2012 0.78
233 Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. Lung Cancer 2010 0.78
234 Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer 2012 0.78
235 Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med 2006 0.78
236 Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? J Gastrointest Surg 2015 0.78
237 Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Pathology 2012 0.78
238 Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. Hum Pathol 2003 0.78
239 NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. Prostate 2014 0.77
240 Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathol Oncol Res 2015 0.77
241 Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World J Urol 2011 0.77
242 Lack of Thy1 (CD90) expression in neuroblastomas is correlated with impaired survival. Pediatr Surg Int 2008 0.77
243 Quality aspects of TMA analysis. Methods Mol Biol 2010 0.77
244 PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol 2015 0.76
245 High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. Hum Pathol 2006 0.76
246 Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leuk Lymphoma 2006 0.76
247 Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J Oral Pathol Med 2013 0.76
248 How radical should surgery be for early esophageal cancer? World J Surg 2011 0.76
249 Role of cyclin D1 amplification and expression in vulvar carcinomas. Hum Pathol 2012 0.76
250 Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget 2017 0.75
251 Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors. Oral Surg Oral Med Oral Pathol Oral Radiol 2011 0.75
252 HER2 amplification in squamous cell carcinomas of the vulva. Histopathology 2013 0.75
253 [Molecular diagnosis and therapy in oncology]. Onkologie 2011 0.75
254 High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Mod Pathol 2006 0.75
255 Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis. Anticancer Res 2007 0.75
256 Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochem Biophys Res Commun 2005 0.75